NCT05347576View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 21, 2022

Primary Completion Date

May 2, 2022

Study Completion Date

May 9, 2022

Conditions
Type2Diabetes
Interventions
DRUG

CKD-393(2)

QD, PO

DRUG

CKD-501, D759, D150, D029

QD, PO

Trial Locations (1)

Unknown

Chonbuk National University Hospital, Jeonju

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT05347576 - A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions | Biotech Hunter | Biotech Hunter